Armando OrlandiΒ· @ArmandOrlandi Β· XΒ·Β· 2 days agoScore70
Body
Cowabunga! π Riding the Metastatic Breast Cancer Wave ππ»ββοΈπ€π» from #ESMO26
HORIZON-Breast06: trastuzumab rezetecan vs chemo in HER2-low disease.
Progression-free survival 16.4 vs 6.8 mo, hazard ratio 0.27.
HER2-low is ADC territory now. Which antibody-drug conjugate, and when?
@OncoAlert @Larvol
126 views Β· 1 like Β· 1 repost Β· 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: Armando Orlandi Β· x.com